Partner Headlines - TEVA

  1. Gurus Are Buying High-Yield Stocks Like WestRock, Target

    GuruFocus
  2. Top Stocks 2015: Biotechs, Wayfair, Netflix, Amazon

    IBD
  3. Takeda Provides Update About New Business Venture in Japan with ...

    Benzinga
  4. 5 Guru Picks in Volatile Biotech Industry

    GuruFocus
  5. NWQ Managers Reduces Stakes in Microsoft, MetLife and Teva Pharmaceutical

    GuruFocus
  6. Benzinga's Top Initiations

    Benzinga
  7. GoPro PT Cut; Chipotle, Bluebird Bio Downgraded

    IBD
  8. Benzinga's Volume Movers

    Benzinga
  9. Top Performing Industries For December 1, 2015

    Benzinga
  10. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga
  11. Teva Announces Proposed Public Offerings Of Amer Depositary Shrs ...

    Benzinga
  12. Teva, Takeda Establish Partnership in Japan; Teva to Own 51% ...

    Benzinga
  13. Teva, Heptares Announce Agreement to Discover and Develop Novel, ...

    Benzinga
  14. Benzinga's Top Upgrades

    Benzinga
  15. Pfizer, Allergan Set To Unveil $150 Billion Inversion

    IBD
  16. John Paulson Increases Holding in Teva Pharmaceutical

    GuruFocus
  17. John Paulson Keeps Gold, Buys Drug Manufacturers in Q3

    GuruFocus
  18. Mylan, Perrigo Face Off As Takeover Vote Nears

    IBD
  19. Ronald Muhlenkamp's Highest-Yielding Stocks

    GuruFocus
  20. Teva Announces Breakthrough Therapy Designation for SD-809 Granted ...

    Benzinga
  21. Allergan Beats Q3 Estimates Amid M&A, Pricing Talk

    IBD
  22. Roche Touts New MS Drug As Legacy Players Hit Snags

    IBD
  23. Allergan Confirms Pfizer Talks

    IBD
  24. Teva Pharmaceutical's

    IBD
  25. Ah the Joys of Theft - My Purloined Portfolio

    GuruFocus
  26. Here's Why Biotechs Fell On Monday

    Benzinga
  27. Teva Launches Generic Avodart Capsules in the US

    Benzinga
  28. Neurocrine Tardive Dyskinesia Drug Hits, Stock Jumps

    IBD
  29. Acorda, Allergan Make Surprise Deal On Ampyra Patent

    IBD
  30. Benzinga's M&A Chatter for Thursday October 1, 2015

    Benzinga
  31. Allergan Guidance Update Gets Mixed Reception

    IBD
  32. U.S. M&A Hits Record As Companies Try To Grow Sales

    IBD
  33. Teva Announces COPAXONE Approved in Japan for Prevention of Relapse ...

    Benzinga
  34. Teva Presents New Reslizumab Data at ERS International Congress ...

    Benzinga
  35. Hedge Fund Menta Capital's Top Stocks Include Teva Pharmaceutical, ...

    GuruFocus
  36. An ETF That Provides Shelter From Stormy Markets

    Benzinga
  37. Teva Announces U.S. Availability of ZECUITY® (sumatriptan iontophoretic ...

    Benzinga
  38. Mylan Confirms USPTO Institutes Inter Partes Review Proceedings ...

    Benzinga
  39. Allergan Modestly Tops Views

    IBD
  40. Allergan Q2 Beats, But Generics Sale Clouds Outlook

    IBD
  41. Israeli Tech Startups Attract Record Funding In Q2

    IBD
  42. 5 Top Medical Stocks Reporting Earnings This Week

    IBD
  43. Teva's Deal-Making Spurs Inflows To Israel ETFs

    Benzinga
  44. Benzinga's Top Upgrades

    Benzinga
  45. IBD 50: 10 Top Stocks Reporting Earnings This Week

    IBD
  46. These 4 Foreign Drug Stocks Have Broken Out Recently

    IBD
  47. 5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen

    IBD
  48. Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up

    IBD
  49. Amgen Stock Clears Buy Point Ahead Of Earnings

    IBD
  50. Stocks In Rebound Mode; Icon, Cadence Break Out

    IBD
  51. Can Health Care Sector Continue its Incredible Run?

    FoxBusiness
  52. Weekly 52-Week Highs Highlight: GIS, AAP, BCR, TEVA

    GuruFocus
  53. Benzinga's Top Upgrades

    Benzinga
  54. Teva Announces European Medicines Agency (EMA) Confirms Successful ...

    Benzinga
  55. Teva Prefers Allergan Unit

    IBD
  56. Benzinga's M&A Chatter for Monday July 27, 2015

    Benzinga
  57. Stocks Fall For Fifth Straight Session On China Woes

    IBD
  58. Allergan CEO: Teva Made A 'Compelling Offer' We Couldn't Refuse

    Benzinga
  59. Market Update: Monday's Top 10 Volume Movers

    Benzinga
  60. Stocks Mired In Red, Hurt By China Weakness; Boot Barn Bounces

    IBD
  61. Market Update: Monday's Mid-Day Movers, China's Stock Market ...

    Benzinga
  62. Stocks In The Red But Off Lows As Shanghai, Europe Weigh

    IBD
  63. Teva Drops Mylan Chase To Buy Allergan Generics Unit

    IBD
  64. Benzinga's Volume Movers

    Benzinga
  65. Teva Confirms Allergan Generics Buy, Drops Mylan Bid

    IBD
  66. U.S. Stocks On Track For Weak Open As Chinese Stocks Sink

    IBD
  67. UPDATE: Mylan Issues Comment on Teva Deal to Buy Allergan's Generic ...

    Benzinga
  68. UPDATE: Teva Withdraws Proposal to Acquire Mylan

    Benzinga
  69. UPDATE: Teva to Acquire Allergan Generics for $40.5 B

    Benzinga
  70. Benzinga's Weekend M&A Chatter

    Benzinga
  71. Teva To Buy Allergan's Generic Drug Unit, Unit Worth ~$45B, Deal ...

    Benzinga
  72. Biotech IPO Boom Gaining Thrust With NantKwest Debut

    IBD
  73. Morning-after pill use increases

    IBD
  74. Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles

    IBD
  75. Rapid7 IPO Pops 52%; Investors Hungry For Blue Buffalo

    IBD
  76. Painkiller Abuse Drives Drugmakers To Innovate

    IBD
  77. Celgene Hits High As Street Applauds Receptos Buyout

    IBD
  78. Teva-Mylan merger opposed

    IBD
  79. Benzinga's Top Initiations

    Benzinga
  80. Medicines Co., Eagle Pharma Up On Analyst Actions

    IBD
  81. Momenta Pharma

    IBD
  82. Momenta Downgraded After Stock Price Doubles

    IBD
  83. Teva-Xenon Arthritis Pain Drug Fails Midstage Trial

    IBD
  84. Wednesday's Mid-Day Movers: Chubb, Rock Creed, RADA Win; Peabody ...

    Benzinga
  85. Unusual Covered Call Opportunity Teva Pharmaceuticals

    Benzinga
  86. Alder Bio Up As Credit Suisse Lauds Migraine Drug

    IBD
  87. New America's IPO Stock Winners: Fitbit, Arista

    IBD
  88. ObamaCare Enables Health Insurer Merger Mania

    IBD
  89. Paul Tudor Jones Buys Stakes in ADP and Visa

    GuruFocus
  90. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  91. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  92. Teva to Present New Findings at the American Headache Society ...

    Benzinga
  93. How High Can Eagle Pharmaceuticals Fly On Teva Deal?

    IBD
  94. Teva's Mylan bid hits snag

    IBD
  95. Teva's Auspex Buyout Pays, But Mylan Bid Hits Snag

    IBD
  96. Teva Advances Pipeline of Movement Disorder Assets with Announcement ...

    Benzinga
  97. Top Biotech Stock Files For New Drug, In Buy Range

    IBD
  98. Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks

    GuruFocus
  99. New Migraine Drugs Could Ease Investors' Headaches

    IBD
  100. Benzinga's M&A Chatter for Tuesday June 9, 2015

    Benzinga
Trading Center